[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.158.81.119. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Commentary
January 12, 2011

Ethical Allocation of Preexposure HIV Prophylaxis

Author Affiliations

Author Affiliations: O’Neill Institute for National and Global Health Law, Georgetown University Law Center, Washington, DC.

JAMA. 2011;305(2):191-192. doi:10.1001/jama.2010.1975

Civil society–led movements transformed global AIDS action from deep skepticism about extending antiretroviral (ARV) treatment in low- and middle-income countries to a historic scaling up of treatment toward universal access. During its first phase (2003-2008), the US President's Emergency Plan for AIDS Relief (PEPFAR)—the largest national commitment to combat a single disease—supported treatment for more than 2 million people, care for more than 10 million people, and prevention of mother-to-child transmission in 16 million pregnancies.1 The Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund), a unique international financing institution, has committed $19.3 billion in 144 countries to support large-scale prevention, treatment, and care, with most resources devoted to AIDS treatment.2

First Page Preview View Large
First page PDF preview
First page PDF preview
×